BIOCYTOGEN PHARMA. H YC1 (I54) - Total Liabilities
Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) has total liabilities worth €1.54 Billion EUR (≈ $1.81 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore I54 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
BIOCYTOGEN PHARMA. H YC1 - Total Liabilities Trend (2021–2025)
This chart illustrates how BIOCYTOGEN PHARMA. H YC1's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does BIOCYTOGEN PHARMA. H YC1 generate to measure how efficiently the company converts operating cash flow to free cash.
BIOCYTOGEN PHARMA. H YC1 Competitors by Total Liabilities
The table below lists competitors of BIOCYTOGEN PHARMA. H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NH SPAC 8
KQ:218410
|
Korea | ₩142.61 Billion |
|
Nanjing Chemical Fibre Co Ltd
SHG:600889
|
China | CN¥893.26 Million |
|
Shenzhen Infinova Ltd
SHE:002528
|
China | CN¥1.81 Billion |
|
Yang Guang Co Ltd
SHE:000608
|
China | CN¥1.77 Billion |
|
Shandong New Beiyang Information Technology Co Ltd
SHE:002376
|
China | CN¥2.02 Billion |
|
Hana Materials Inc
KQ:166090
|
Korea | ₩221.93 Billion |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
China | CN¥1.84 Billion |
|
Grupo Supervielle SA
NYSE:SUPV
|
USA | $6.51 Trillion |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOCYTOGEN PHARMA. H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see I54 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOCYTOGEN PHARMA. H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below shows the annual total liabilities of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.54 Billion ≈ $1.81 Billion |
-2.02% |
| 2024-12-31 | €1.58 Billion ≈ $1.84 Billion |
-4.96% |
| 2023-12-31 | €1.66 Billion ≈ $1.94 Billion |
+0.60% |
| 2022-12-31 | €1.65 Billion ≈ $1.93 Billion |
+56.93% |
| 2021-12-31 | €1.05 Billion ≈ $1.23 Billion |
-- |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more